Andes D, Diekema D J, Pfaller M A, Prince R A, Marchillo K, Ashbeck J, Hou J
Department of Medicine, University of Wisconsin, Madison, Wisconsin Madison, WI 53792, USA.
Antimicrob Agents Chemother. 2008 Feb;52(2):539-50. doi: 10.1128/AAC.01061-07. Epub 2007 Dec 10.
Multiple in vivo studies have characterized the pharmacodynamics of drugs from the triazole and polyene antifungal drug classes. Fewer studies have investigated these pharmacodynamic relationships for the echinocandin drug class. We used a neutropenic murine model of disseminated Candida albicans, Candida tropicalis, and Candida glabrata infection to characterize the time course of activity of the new echinocandin anidulafungin. The pharmacokinetic-pharmacodynamic (PK-PD) indices (the percentage of time that the drug concentration was above the MIC, the ratio of the area under the concentration-time curve from 0 to 24 h [AUC(0-24)] to the MIC, and the ratio of the maximum serum drug concentration [C(max)] to the MIC) were correlated with in vivo efficacy, as measured by organism numbers in kidney cultures after 96 h of therapy. The kinetics following intraperitoneal anidulafungin dosing in neutropenic infected mice were monitored. Peak levels and AUCs were linear over the 16-fold dose range studied. The drug elimination half-life in serum ranged from 14 to 24 h. Single-dose postantifungal-effect studies demonstrated prolonged suppression of organism regrowth after serum anidulafungin levels had fallen below the MIC. Of the four dosing intervals studied, treatment with the more widely spaced dosing regimens was most efficacious, suggesting the C(max)/MIC ratio as the PK-PD index most predictive of efficacy. Nonlinear regression analysis suggested that both the C(max)/MIC and AUC/MIC ratios were strongly predictive of treatment success. Studies were then conducted with 13 additional C. albicans, C. tropicalis, and C. glabrata isolates with various anidulafungin susceptibilities (MICs of anidulafungin for these strains, 0.015 to 2.0 microg/ml) to determine if similar C(max)/MIC and AUC(0-24)/MIC ratios for these isolates were associated with efficacy. The anidulafungin exposures associated with efficacy were similar among Candida species.
多项体内研究已对三唑类和多烯类抗真菌药物的药效学进行了表征。针对棘白菌素类药物的这些药效学关系的研究较少。我们使用了播散性白色念珠菌、热带念珠菌和光滑念珠菌感染的中性粒细胞减少小鼠模型,以表征新型棘白菌素阿尼芬净的活性随时间变化的过程。药代动力学 - 药效学(PK - PD)指标(药物浓度高于最低抑菌浓度(MIC)的时间百分比、0至24小时浓度 - 时间曲线下面积(AUC(0 - 24))与MIC的比值以及最大血清药物浓度(C(max))与MIC的比值)与体内疗效相关,疗效通过治疗96小时后肾脏培养物中的菌数来衡量。监测了中性粒细胞减少感染小鼠腹腔注射阿尼芬净后的动力学。在所研究的16倍剂量范围内,峰值水平和AUC呈线性关系。血清中药物消除半衰期为14至24小时。单剂量抗真菌后效应研究表明,血清阿尼芬净水平降至MIC以下后,对菌体重生长的抑制作用持续存在。在所研究的四个给药间隔中,给药间隔时间间隔较长的治疗方案最有效,这表明C(max)/MIC比值是最能预测疗效的PK - PD指标。非线性回归分析表明,C(max)/MIC和AUC/MIC比值均强烈预测治疗成功。然后对另外13株具有不同阿尼芬净敏感性(这些菌株对阿尼芬净的MIC为0.015至2.0μg/ml)的白色念珠菌、热带念珠菌和光滑念珠菌分离株进行了研究,以确定这些分离株类似 的C(max)/MIC和AUC(0 - 24)/MIC比值是否与疗效相关。不同念珠菌属中与疗效相关的阿尼芬净暴露情况相似。